|
US2011A
(en)
|
|
1841-03-18 |
|
Appabatxts for piling saws |
|
US154516A
(en)
|
|
1874-08-25 |
|
Improvement in pistons for steam-engines |
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US3941763A
(en)
|
1975-03-28 |
1976-03-02 |
American Home Products Corporation |
PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
EP0088046B1
(de)
|
1982-02-17 |
1987-12-09 |
Ciba-Geigy Ag |
Lipide in wässriger Phase
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
EP0143949B1
(en)
|
1983-11-01 |
1988-10-12 |
TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION |
Pharmaceutical composition containing urokinase
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
FR2560212B1
(fr)
|
1984-02-24 |
1989-12-29 |
Unicet |
Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
|
|
US4965188A
(en)
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
|
EP0272253A4
(en)
|
1986-03-07 |
1990-02-05 |
Massachusetts Inst Technology |
METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
|
|
US5453269A
(en)
|
1986-04-14 |
1995-09-26 |
The General Hospital Corporation |
Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
|
US5559212A
(en)
|
1988-04-06 |
1996-09-24 |
Alfacell Corporation |
Frog embryo and egg-derived tumor cell anti-proliferation protein
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
IL88377A
(en)
|
1988-11-14 |
1996-09-12 |
Yeda Res & Dev |
Cloning and expression of a protein which modulates cellular response to type I interferon
|
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
FR2653445B1
(fr)
|
1989-10-20 |
1994-07-29 |
Centre Nat Rech Scient |
Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante.
|
|
US5889151A
(en)
|
1989-10-20 |
1999-03-30 |
Societe Leb-Tech |
Purified human alpha interferon receptor
|
|
US5840840A
(en)
|
1990-04-17 |
1998-11-24 |
The United States Of America As Represented By The Department Of Health And Human Services |
Selective RNase cytotoxic reagents
|
|
US5525491A
(en)
|
1991-02-27 |
1996-06-11 |
Creative Biomolecules, Inc. |
Serine-rich peptide linkers
|
|
ES2133285T3
(es)
|
1991-04-17 |
1999-09-16 |
Medisup Int Nv |
Polipeptidos hidrosolubles que tienen una alta afinidad para los interferones alfa y beta.
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
MX9204374A
(es)
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
|
US5994514A
(en)
|
1991-08-14 |
1999-11-30 |
Genentech, Inc. |
Immunoglobulin variants
|
|
DE69214656T2
(de)
|
1991-08-30 |
1997-03-13 |
Genentech Inc |
Therapeutisches verfahren zur behandlung von iddm
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
US5470582A
(en)
|
1992-02-07 |
1995-11-28 |
Syntex (U.S.A.) Inc. |
Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
|
|
EP0563487A1
(en)
|
1992-03-31 |
1993-10-06 |
Laboratoire Europeen De Biotechnologie S.A. |
Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
|
|
CA2142007C
(en)
|
1992-08-11 |
2007-10-30 |
Robert Glen Urban |
Immunomodulatory peptides
|
|
US5423269A
(en)
|
1992-11-24 |
1995-06-13 |
Gunderson, Inc. |
Railroad well car body including side sill reinforcing walkway structure
|
|
GB9300686D0
(en)
|
1993-01-15 |
1993-03-03 |
Imp Cancer Res Tech |
Compounds for targeting
|
|
US20030108548A1
(en)
|
1993-06-01 |
2003-06-12 |
Bluestone Jeffrey A. |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
IL107378A
(en)
|
1993-10-24 |
2005-05-17 |
Yeda Res & Dev |
SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US5932462A
(en)
|
1995-01-10 |
1999-08-03 |
Shearwater Polymers, Inc. |
Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
|
|
US6348343B2
(en)
|
1995-02-24 |
2002-02-19 |
Genentech, Inc. |
Human DNase I variants
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5780027A
(en)
|
1995-07-14 |
1998-07-14 |
Meiogen Biotechnology Corporation |
Methods of treatment of down syndrome by interferon antagonists
|
|
US6127977A
(en)
|
1996-11-08 |
2000-10-03 |
Cohen; Nathan |
Microstrip patch antenna with fractal structure
|
|
US5989830A
(en)
|
1995-10-16 |
1999-11-23 |
Unilever Patent Holdings Bv |
Bifunctional or bivalent antibody fragment analogue
|
|
US6482626B2
(en)
|
1996-02-05 |
2002-11-19 |
Genentech, Inc. |
Human DNase
|
|
US6716974B1
(en)
|
1996-05-31 |
2004-04-06 |
Maine Medical Center Research Institute |
Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
|
|
US6391607B1
(en)
|
1996-06-14 |
2002-05-21 |
Genentech, Inc. |
Human DNase I hyperactive variants
|
|
ES2300113T3
(es)
|
1996-08-02 |
2008-06-01 |
Bristol-Myers Squibb Company |
Un procedimiento para inhibir toxicidad inducida por inmunoglobulinas que resulta del uso de inmunoglobulinas en terapia y diagnostico in vivo.
|
|
US7247302B1
(en)
|
1996-08-02 |
2007-07-24 |
Bristol-Myers Squibb Company |
Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
ES2191827T3
(es)
|
1996-10-17 |
2003-09-16 |
Immunomedics Inc |
Conjugado de toxina no antigenica y proteina de fusion de un sistema receptor de penetracion intracelular.
|
|
US6653104B2
(en)
|
1996-10-17 |
2003-11-25 |
Immunomedics, Inc. |
Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
IL132560A0
(en)
|
1997-05-02 |
2001-03-19 |
Genentech Inc |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
US20030054359A1
(en)
|
1997-06-16 |
2003-03-20 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US20020192659A1
(en)
|
1997-09-17 |
2002-12-19 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US5840296A
(en)
|
1997-10-15 |
1998-11-24 |
Raines; Ronald T. |
Engineered cytotoxic ribonuclease A
|
|
US6280991B1
(en)
|
1997-10-15 |
2001-08-28 |
Wisconsin Alumni Research Foundation |
Engineered cytotoxic ribonclease
|
|
JP4601163B2
(ja)
|
1997-12-19 |
2010-12-22 |
メルク・セローノ・ソシエテ・アノニム |
Ｉｆｎａｒ２／ｉｆｎ複合体
|
|
IL138608A0
(en)
|
1998-04-02 |
2001-10-31 |
Genentech Inc |
Antibody variants and fragments thereof
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US20030175778A1
(en)
|
1998-06-05 |
2003-09-18 |
Jian Ni |
Interferon Receptor HKAEF92
|
|
WO2000009560A2
(en)
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
WO2000022093A2
(en)
|
1998-09-23 |
2000-04-20 |
Cleveland Clinic Foundation |
Novel interferon stimulated and repressed genes
|
|
AUPP670698A0
(en)
|
1998-10-23 |
1998-11-19 |
Monash University |
A method of regulation
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
US6239257B1
(en)
|
1998-12-30 |
2001-05-29 |
Alfacell Corporation |
Family of proteins belonging to the pancreatic ribonuclease a superfamily
|
|
PL220113B1
(pl)
|
1999-01-15 |
2015-08-31 |
Genentech Inc |
Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
EP1194451A1
(en)
|
1999-07-02 |
2002-04-10 |
Genentech, Inc. |
Fusion peptides comprising a peptide ligand domain and a multimerization domain
|
|
US6175003B1
(en)
|
1999-09-10 |
2001-01-16 |
Alfacell Corporation |
Nucleic acids encoding ribonucleases and methods of making them
|
|
AU1084901A
(en)
|
1999-10-14 |
2001-04-23 |
Martha S. Hayden-Ledbetter |
Dna vaccines encoding antigen linked to a domain that binds cd40
|
|
WO2001077394A1
(en)
|
2000-04-10 |
2001-10-18 |
Mount Sinai School Of Medicine Of New York University |
Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
|
|
MXPA03000105A
(es)
|
2000-06-28 |
2004-09-13 |
Glycofi Inc |
Metodo para producir glicoproteinas modificadas.
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
ES2363761T3
(es)
|
2001-01-09 |
2011-08-16 |
Baylor Research Institute |
Procedimientos para el tratamiento de enfermedades autoinmunitarias en un sujeto y en ensayos de diagnóstico in vitro.
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
NZ545176A
(en)
|
2001-01-29 |
2008-05-30 |
Biogen Idec Inc |
Modified antibodies reactive with CD20 and methods of use
|
|
US7319139B2
(en)
|
2001-01-29 |
2008-01-15 |
Biogen Idec, Inc. |
TAG-72 specific CH2 domain deleted antibodies
|
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
|
CN1330664C
(zh)
|
2001-03-07 |
2007-08-08 |
默克专利有限公司 |
用于含杂合同种型抗体部分的蛋白质的表达技术
|
|
JP4586310B2
(ja)
|
2001-07-04 |
2010-11-24 |
株式会社Ihi |
セラミックス複合部材の製造方法
|
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
|
US20060040262A1
(en)
|
2002-12-27 |
2006-02-23 |
Morris David W |
Novel compositions and methods in cancer
|
|
IL147414A0
(en)
|
2001-12-31 |
2002-08-14 |
Yeda Res & Dev |
Ifnar2 mutants, their production and use
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
CA2478011C
(en)
|
2002-03-01 |
2013-05-21 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
AU2003244093A1
(en)
|
2002-05-17 |
2003-12-02 |
Aritoshi Iida |
Method of detecting gene polymorphism
|
|
CA2489446A1
(en)
|
2002-06-14 |
2003-12-24 |
Wisconsin Alumni Research Foundation |
Ribonuclease zymogen design
|
|
EP1534335B9
(en)
|
2002-08-14 |
2016-01-13 |
Macrogenics, Inc. |
Fcgammariib-specific antibodies and methods of use thereof
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
EP2298805A3
(en)
|
2002-09-27 |
2011-04-13 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
DK1562972T3
(da)
|
2002-10-15 |
2010-12-06 |
Facet Biotech Corp |
Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
|
|
JP2006515747A
(ja)
|
2002-11-01 |
2006-06-08 |
ジェネンテック・インコーポレーテッド |
免疫関連疾患の治療のための組成物と方法
|
|
GB2395337B
(en)
|
2002-11-14 |
2005-12-28 |
Gary Michael Wilson |
Warning Unit
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US7067298B2
(en)
|
2003-03-31 |
2006-06-27 |
Ambion, Inc. |
Compositions and methods of using a synthetic Dnase I
|
|
US7666417B2
(en)
|
2003-04-22 |
2010-02-23 |
Fred Hutchinson Cancer Research Center |
Methods and compositions for treating autoimmune diseases or conditions
|
|
CN100409897C
(zh)
|
2003-04-23 |
2008-08-13 |
梅达雷克斯公司 |
1型干扰素拮抗剂在制备治疗患有炎症性肠病的患者的药物中的用途
|
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040266993A1
(en)
|
2003-06-30 |
2004-12-30 |
Evans Glen A. |
Non-immunoglobulin binding polypeptides
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
EP2502935B1
(en)
|
2003-08-22 |
2017-03-29 |
Biogen MA Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
JP4745972B2
(ja)
|
2003-10-21 |
2011-08-10 |
メルク セローノ ソシエテ アノニム |
クロマチンインスレーターとして作用する極小ｄｎａ配列、及びタンパク質発現におけるその使用
|
|
ME01775B
(me)
|
2003-11-05 |
2011-02-28 |
Glycart Biotechnology Ag |
Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
|
|
CA2545603A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
|
|
WO2005063815A2
(en)
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
|
WO2005077981A2
(en)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
|
BRPI0417916A
(pt)
|
2003-12-31 |
2007-04-10 |
Merck Patent Gmbh |
proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
|
|
CA2552788C
(en)
|
2004-01-12 |
2013-09-24 |
Applied Molecular Evolution, Inc. |
Fc region variants
|
|
AU2005214361B2
(en)
|
2004-02-13 |
2011-03-24 |
Immunomedics, Inc. |
Fusion proteins containing recombinant cytotoxic RNAses
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US8470315B2
(en)
|
2004-04-13 |
2013-06-25 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
JP2008505174A
(ja)
|
2004-07-15 |
2008-02-21 |
ゼンコー・インコーポレイテッド |
最適化Ｆｃ変異体
|
|
RU2007108538A
(ru)
|
2004-08-11 |
2008-09-20 |
Трабьон Фармасьютикалз, Инк. (Us) |
Слитые со связывающим доменом белки
|
|
JP2006071409A
(ja)
|
2004-09-01 |
2006-03-16 |
Kansai Tlo Kk |
シェーグレン症候群診断キット
|
|
WO2006031994A2
(en)
|
2004-09-14 |
2006-03-23 |
Xencor, Inc. |
Monomeric immunoglobulin fc domains
|
|
EP1796722A1
(en)
|
2004-10-07 |
2007-06-20 |
Universität Zürich |
Type i interferon blocking agents for prevention and treatment of psoriasis
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
DE102005009219A1
(de)
|
2005-02-25 |
2006-08-31 |
Martin-Luther-Universität Halle-Wittenberg |
Ribonuclease-Tandemenzyme und Verfahren zu ihrer Herstellung
|
|
WO2006105062A2
(en)
|
2005-03-29 |
2006-10-05 |
Verenium Corporation |
Altered antibody fc regions and uses thereof
|
|
EP1888649A2
(en)
|
2005-05-09 |
2008-02-20 |
GlycArt Biotechnology AG |
Antigen binding molecules having modified fc regions and altered binding to fc receptors
|
|
JP5114392B2
(ja)
|
2005-06-16 |
2013-01-09 |
ウイスコンシン アラムニ リサーチ ファンデーション |
細胞傷害性リボヌクレアーゼ変異株
|
|
EP1896579A2
(en)
|
2005-06-16 |
2008-03-12 |
Wisconsin Alumni Research Foundation |
Cytotoxic ribonuclease variants
|
|
US7732167B2
(en)
|
2005-06-17 |
2010-06-08 |
Regeneron Pharmaceuticals, Inc. |
Interferon-α/β binding fusion proteins and therapeutic uses thereof
|
|
US20080279850A1
(en)
|
2005-07-25 |
2008-11-13 |
Trubion Pharmaceuticals, Inc. |
B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
|
|
HUE026303T2
(hu)
|
2005-07-25 |
2016-06-28 |
Emergent Product Dev Seattle |
B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
|
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
|
US7608395B2
(en)
|
2005-09-15 |
2009-10-27 |
Baylor Research Institute |
Systemic lupus erythematosus diagnostic assay
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
JP4860702B2
(ja)
|
2005-10-21 |
2012-01-25 |
エフ．ホフマン−ラ ロシュ アーゲー |
ポリペプチドのリコンビナント発現のための方法
|
|
US7892740B2
(en)
|
2006-01-19 |
2011-02-22 |
The University Of Chicago |
Prognosis and therapy predictive markers and methods of use
|
|
WO2007110205A2
(en)
|
2006-03-24 |
2007-10-04 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
|
BRPI0710011A2
(pt)
|
2006-04-14 |
2011-08-02 |
Trubion Pharmaceuticals Inc |
proteìnas de ligação compreendendo articulação de imunoglobulina e regiões fc dotadas de funções efetoras fc alteradas
|
|
WO2007122511A2
(en)
|
2006-04-21 |
2007-11-01 |
Mab-Factory Gmbh |
Antibody-rnase-conjugate
|
|
WO2007136789A2
(en)
|
2006-05-19 |
2007-11-29 |
Medimmune, Inc. |
Methods of preventing, treating or ameliorating enhanced respiratory disease via innate immune mechanisms
|
|
GB0611444D0
(en)
|
2006-06-09 |
2006-07-19 |
Medical Res Council Technology |
Rnase H2 complex and genes therefor
|
|
MX2008015524A
(es)
|
2006-06-12 |
2009-01-13 |
Trubion Pharmaceuticals Inc |
Proteinas de union multivalentes monocatenarias con funcion efectora.
|
|
US20090182127A1
(en)
|
2006-06-22 |
2009-07-16 |
Novo Nordisk A/S |
Production of Bispecific Antibodies
|
|
US20080248959A1
(en)
|
2006-07-21 |
2008-10-09 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
|
AU2007278994B2
(en)
|
2006-07-24 |
2013-08-15 |
Biorexis Pharmaceutical Corporation |
Exendin fusion proteins
|
|
US8198063B1
(en)
|
2006-09-12 |
2012-06-12 |
Pro Zyme, Inc |
Rapid deglycosylation of glycoproteins
|
|
EP1905841A1
(en)
|
2006-09-25 |
2008-04-02 |
Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; |
Trex1 as a marker for lupus erythematosus
|
|
US8277797B2
(en)
|
2006-11-22 |
2012-10-02 |
The Regents Of The University Of California |
Interferon-β production modulating Listeria strains and methods for using same
|
|
EP2144930A1
(en)
|
2007-04-18 |
2010-01-20 |
ZymoGenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
|
EP2076590A4
(en)
|
2007-05-03 |
2011-06-01 |
Medimmune Llc |
SELF-IMMUNE DISEASE SELF-ANTIBODY MARKERS
|
|
AU2008254951A1
(en)
|
2007-05-14 |
2008-11-27 |
Biogen Idec Ma Inc. |
Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto
|
|
US20090258005A1
(en)
|
2007-05-29 |
2009-10-15 |
Trubion Pharmaceuticals Inc. |
Therapeutic compositions and methods
|
|
CN101842389A
(zh)
|
2007-06-12 |
2010-09-22 |
惠氏有限责任公司 |
抗cd20治疗组合物和方法
|
|
WO2009023386A2
(en)
|
2007-07-06 |
2009-02-19 |
Trubion Pharmaceuticals, Inc. |
Binding peptides having a c-terminally disposed specific binding domain
|
|
WO2009015345A1
(en)
|
2007-07-25 |
2009-01-29 |
Amgen Inc. |
Pharmaceutical compositions comprising fc fusion proteins
|
|
WO2009012600A1
(en)
|
2007-07-26 |
2009-01-29 |
Novagen Holding Corporation |
Fusion proteins
|
|
EP2209487A4
(en)
|
2007-10-15 |
2012-06-20 |
Univ North Carolina |
Human factor ix variants with an extended half life
|
|
EP2220125A4
(en)
|
2007-11-13 |
2010-12-29 |
Sapphire Energy Inc |
PRODUCTION OF FC HYBRID POLYPEPTIDES IN EUKARYOTIC ALGAE
|
|
DK2235064T3
(en)
|
2008-01-07 |
2016-01-11 |
Amgen Inc |
A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
|
|
AU2009234277B2
(en)
|
2008-04-11 |
2014-12-04 |
Aptevo Research And Development Llc |
CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
US9636420B2
(en)
|
2008-07-23 |
2017-05-02 |
Hanmi Science Co., Ltd. |
Polypeptide complex comprising non-peptidyl polymer having three functional ends
|
|
JP2012503985A
(ja)
|
2008-09-26 |
2012-02-16 |
ジェネンテック， インコーポレイテッド |
ループスの治療、診断、モニタリング方法
|
|
EP2334695B1
(en)
|
2008-10-01 |
2015-12-23 |
Quintessence Biosciences, Inc. |
Therapeutic ribonucleases
|
|
US10837020B2
(en)
|
2009-04-22 |
2020-11-17 |
Massachusetts Institute Of Technology |
Innate immune suppression enables repeated delivery of long RNA molecules
|
|
EP2421563B1
(en)
|
2009-04-22 |
2017-04-12 |
Massachusetts Institute of Technology |
Innate immune suppression enables repeated delivery of long rna molecules
|
|
EP3248618A1
(en)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Innate immune suppression enables repeated delivery of long rna molecules
|
|
WO2010151792A1
(en)
|
2009-06-26 |
2010-12-29 |
Regeneron Pharmaceuticals, Inc. |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
DK3202898T3
(en)
*
|
2009-11-02 |
2019-01-14 |
Univ Washington |
THERAPEUTIC NUCLEASE COMPOSITIONS AND PROCEDURES
|
|
BR112012013330A2
(pt)
|
2009-12-02 |
2017-03-28 |
Acceleron Pharma Inc |
composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
|
|
WO2011108502A1
(ja)
|
2010-03-02 |
2011-09-09 |
協和発酵キリン株式会社 |
改変抗体組成物
|
|
EP2556087A1
(en)
|
2010-04-09 |
2013-02-13 |
Novozymes Biopharma DK A/S |
Albumin derivatives and variants
|
|
JP6040148B2
(ja)
|
2010-04-20 |
2016-12-07 |
ゲンマブ エー／エス |
ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
|
|
SI2580243T1
(sl)
|
2010-06-09 |
2020-02-28 |
Genmab A/S |
Protitelesa proti humanemu CD38
|
|
JP2013537416A
(ja)
|
2010-08-13 |
2013-10-03 |
メディミューン リミテッド |
変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
|
|
MX352929B
(es)
|
2010-11-05 |
2017-12-13 |
Zymeworks Inc |
DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
|
|
US9334331B2
(en)
|
2010-11-17 |
2016-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Bispecific antibodies
|
|
WO2012068636A1
(en)
|
2010-11-26 |
2012-05-31 |
The University Of Melbourne |
Methods and compositions comprising antagonists of type 1 interferon-mediated signalling for reducing a neuroinflammatory response in the central nervous system
|
|
UY33827A
(es)
|
2010-12-22 |
2012-07-31 |
Abbott Lab |
Proteínas de unión a media-inmunoglobulina y sus usos
|
|
TWI529163B
(zh)
|
2011-01-25 |
2016-04-11 |
陶氏農業科學公司 |
用於製備４－胺基－５－氟－３－鹵素－６－（經取代之）吡啶甲酸酯的方法
|
|
RU2636029C2
(ru)
|
2011-02-01 |
2017-11-17 |
Генмаб А/С |
Человеческие антитела и конъюгаты антитело-препарат против cd74
|
|
MX363013B
(es)
|
2011-02-25 |
2019-03-04 |
Recombinetics Inc |
Animales genéticamente modificados y métodos para su obtención.
|
|
JP6177231B2
(ja)
|
2011-04-20 |
2017-08-09 |
ゲンマブ エー／エス |
Ｈｅｒ２に対する二重特異性抗体
|
|
US20140170148A1
(en)
|
2011-04-20 |
2014-06-19 |
Genmab A/S |
Bispecific antibodies against her2
|
|
WO2012143524A2
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
|
KR102055331B1
(ko)
|
2011-04-21 |
2019-12-12 |
아이오니스 파마수티컬즈, 인코포레이티드 |
B형 간염 바이러스(hbv) 발현 조절
|
|
AU2012249360B2
(en)
|
2011-04-29 |
2015-12-24 |
University Of Washington |
Therapeutic nuclease compositions and methods
|
|
WO2013003475A1
(en)
|
2011-06-27 |
2013-01-03 |
Cellscript, Inc. |
Inhibition of innate immune response
|
|
US20140178479A1
(en)
|
2011-08-12 |
2014-06-26 |
Perosphere, Inc. |
Concentrated Felbamate Formulations for Parenteral Administration
|
|
WO2013059299A1
(en)
|
2011-10-17 |
2013-04-25 |
The Uab Research Foundation |
Antibodies for interferon subtypes and interferon/interferon receptor ternary complex and uses thereof
|
|
US10344050B2
(en)
|
2011-10-27 |
2019-07-09 |
Genmab A/S |
Production of heterodimeric proteins
|
|
KR102052774B1
(ko)
|
2011-11-04 |
2019-12-04 |
자임워크스 인코포레이티드 |
Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
|
|
ES2843054T3
(es)
*
|
2012-05-10 |
2021-07-15 |
Zymeworks Inc |
Construcciones heteromultiméricas de cadenas pesadas de inmunoglobulina con mutaciones en el dominio Fc
|
|
WO2013180295A1
(ja)
|
2012-06-01 |
2013-12-05 |
日本電信電話株式会社 |
パケット転送処理方法およびパケット転送処理装置
|
|
KR102320059B1
(ko)
|
2012-06-13 |
2021-11-01 |
아스트라제네카 아베 |
항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획
|
|
WO2014004586A1
(en)
*
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
GB2503883A
(en)
|
2012-07-09 |
2014-01-15 |
King S College London |
Variant IgE with reduced affinity to CD23
|
|
CN104640562A
(zh)
*
|
2012-07-13 |
2015-05-20 |
酵活有限公司 |
包含抗-cd3构建体的双特异性不对称异二聚体
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
US10047167B2
(en)
|
2013-03-15 |
2018-08-14 |
Eli Lilly And Company |
Methods for producing fabs and bi-specific antibodies
|
|
EA201890895A1
(ru)
|
2013-03-15 |
2019-02-28 |
Зинджения, Инк. |
Мультивалентные и моновалентные мультиспецифические комплексы и их применение
|
|
WO2014172309A2
(en)
|
2013-04-18 |
2014-10-23 |
The United States Of America As Represented By The Secretary Of The Army, On Behalf Of The United |
Therapeutic compositions for neutralizing type i interferons, and methods of use
|
|
NZ753995A
(en)
|
2013-05-30 |
2022-07-01 |
Kiniksa Pharmaceuticals Ltd |
Oncostatin m receptor antigen binding proteins
|
|
BR112015029788B1
(pt)
|
2013-05-31 |
2024-01-02 |
Zymeworks Inc |
HETERO-MULTÍMERO, USO E MÉTODO PARA PREPARAR DO MESMO, COMPOSIÇÃO FARMACÊUTICA E MÉTODO PARA REDUZIR FUNÇÃO EFETORA DE UM CONSTRUTO IgG FC
|
|
WO2015066550A1
(en)
*
|
2013-10-31 |
2015-05-07 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-albumin fusions and methods
|
|
JP6873701B2
(ja)
|
2014-01-15 |
2021-05-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ＦｃＲｎ結合特性が改変されているＦｃ領域変異体
|
|
US9300829B2
(en)
|
2014-04-04 |
2016-03-29 |
Canon Kabushiki Kaisha |
Image reading apparatus and correction method thereof
|
|
KR20150140177A
(ko)
|
2014-06-05 |
2015-12-15 |
한미약품 주식회사 |
단백질 및 펩타이드의 면역원성을 감소시키는 방법
|
|
WO2016069889A1
(en)
*
|
2014-10-31 |
2016-05-06 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-transferrin fusions and methods
|
|
EP3227328B1
(en)
|
2014-12-05 |
2022-10-05 |
Merck Patent GmbH |
Domain-exchanged antibody
|
|
WO2016087648A1
(en)
|
2014-12-05 |
2016-06-09 |
Universität Für Bodenkultur Wien |
Immunoglobulins with incorporated heterologous ch3 domains resulting in a prolonged half-life
|
|
MA41375A
(fr)
|
2015-01-22 |
2017-11-28 |
Lilly Co Eli |
Anticorps igg bispécifiques et leurs procédés de préparation
|
|
US11028182B2
(en)
|
2015-05-13 |
2021-06-08 |
Zymeworks Inc. |
Antigen-binding constructs targeting HER2
|
|
US9693229B2
(en)
|
2015-11-05 |
2017-06-27 |
International Business Machines Corporation |
Logical subscriber identification module (SIM)
|
|
CN107007606B
(zh)
|
2016-02-04 |
2021-10-26 |
南京舒鹏生物科技有限公司 |
一种用于干燥综合症预防及治疗的药物及其组合
|
|
JP7082604B2
(ja)
|
2016-03-21 |
2022-06-08 |
マレンゴ・セラピューティクス，インコーポレーテッド |
多重特異性および多機能性分子ならびにその使用
|
|
WO2017185177A1
(en)
|
2016-04-25 |
2017-11-02 |
Zymeworks Inc. |
Methods of using bispecific antigen-binding constructs targeting her2
|
|
DK3448419T5
(da)
|
2016-04-29 |
2024-09-09 |
Pfizer |
Interferon-beta-antistoffer og anvendelser deraf
|
|
US20190241878A1
(en)
|
2016-07-01 |
2019-08-08 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
|
CA3034768A1
(en)
|
2016-08-26 |
2018-03-01 |
Sanofi |
Multispecific antibodies facilitating selective light chain pairing
|
|
US10072296B2
(en)
|
2016-09-19 |
2018-09-11 |
The Charlotte Mecklenburg Hospital Authority |
Compositions and methods for sjögren's syndrome
|
|
JP6349003B1
(ja)
|
2017-03-17 |
2018-06-27 |
東洋ビーネット株式会社 |
耐熱性ルシフェラーゼ
|
|
CN111315767B
(zh)
|
2017-08-22 |
2025-03-18 |
萨纳生物有限责任公司 |
可溶性干扰素受体及其用途
|
|
CN113597319A
(zh)
|
2019-01-04 |
2021-11-02 |
分解治疗有限责任公司 |
用核酸酶融合蛋白治疗干燥症
|
|
EP4171614A1
(en)
|
2020-06-29 |
2023-05-03 |
Resolve Therapeutics, LLC |
Treatment of sjogren's syndrome with nuclease fusion proteins
|